The role and efficacy of subcutaneous injection of evantuzumab (Rybrevant Faspro)

Subcutaneous injection of evantumumab (Rybrevant Faspro) is a dual-action anticancer drug mainly used to treat non-small cell lung cancer (NSCLC). The drug is unique in its combination of two active ingredients: Amivantumab and hyaluronidase. They work synergistically to effectively target cancer cells, thereby increasing the effectiveness of treatment.

Evantumumab is a targeted drug that specifically targets two key proteins on the surface of cancer cells - epidermal growth factor receptor (EGFR) and MET. By blocking signaling from these proteins, evantumumab is able to interfere with tumor cell growth and proliferation, especially in the presence of specific EGFR mutations. In addition, evantumumab can also enhance the response of the immune system, help immune cells recognize and destroy cancer cells, and further improve the anti-tumor effect.

Hyaluronidase plays an important role in the drug administration process. The function of this enzyme is to temporarily relax the subcutaneous tissue, thereby improving the absorption of drugs. The effect of hyaluronidase is local and reversible, lasting approximately 24 to 48 hours, which allows the drug to better penetrate into the tissue after injection and improve the efficiency of treatment.

In summary, evantumumab is a combination drug of bispecific antibodies and endoglycosidase and has a unique therapeutic mechanism. Its evantuzumab ingredient effectively targets EGFR and MET receptors, which can accurately inhibit the growth of tumor cells; the hyaluronidase ingredient improves the therapeutic effect by improving the local absorption of the drug. This innovative combination makes evantumumab an important treatment option for non-small cell lung cancer, providing new hope for patients.

Reference materials:https://www.drugs.com/rybrevant-faspro.html